Kane Biotech Inc. (CVE:KNE – Get Free Report)’s stock price traded down 4.5% during trading on Monday . The stock traded as low as C$0.11 and last traded at C$0.11. 26,500 shares were traded during mid-day trading, a decline of 22% from the average session volume of 34,000 shares. The stock had previously closed at C$0.11.
Kane Biotech Stock Performance
The company has a debt-to-equity ratio of 1,164.24, a quick ratio of 0.39 and a current ratio of 0.82. The firm has a market cap of C$13.91 million, a P/E ratio of -3.50 and a beta of 0.52. The business’s 50-day simple moving average is C$0.11 and its 200 day simple moving average is C$0.13.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Stories
- Five stocks we like better than Kane Biotech
- What is a buyback in stocks? A comprehensive guide for investors
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- Expert Stock Trading Psychology Tips
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
